ADC Therapeutics competitors and similar companiesClear all

ADC Therapeutics's competitors and similar companies include Mersana Therapeutics, ImmunoGen, Immunomedics, Araris Biotech and Ajinomoto Bio-Pharma Services.
ADC Therapeutics
ADC Therapeutics
ADC Therapeutics is a biotechnology company that develops drug conjugates for the treatment of both solid and haematological cancers.
Mersana Therapeutics
Mersana Therapeutics
Mersana Therapeutics is a clinical-stage biotechnology company developing antibody-drug conjugate (ADC) platforms.
ImmunoGen
ImmunoGen
ImmunoGen is a biotechnology company focused on the development of antibody-drug conjugates (ADCs) to improve outcomes for cancer patients.
Immunomedics
Immunomedics
Immunomedics is a developer of monoclonal antibody-based products for the targeted treatment of cancer.
Araris Biotech
Araris Biotech
Araris Biotech is a biotechnology company with a new antibody-drug conjugate (ADC)-linker technology.
Ajinomoto Bio-Pharma Services
Ajinomoto Bio-Pharma Services
Ajinomoto Bio-Pharma Services (formerly known as (Ajinomoto Althea) is a contract development and manufacturing organization (CDMO) that engages in process development, drug substance manufacturing, and drug product manufacturing.
Founding Date
Founding Date
2010
Founding Date
2005
Founding Date
1981
Founding Date
1982
Founding Date
2019
Founding Date
1998
Type
Type
Public
Type
Public
Type
Public
Type
Subsidiary
Type
Private
Type
Subsidiary
Tags
Locations
Locations
Epalinges, CH HQ
Greater London, GB
New Providence, US
San Mateo, US
Locations
Cambridge, US HQ
Locations
Waltham, US HQ
Locations
Morris Plains, US HQ
Locations
Zürich, CH HQ
Locations
San Diego, US HQ
Wetteren, BE
Visakhapatnam, IN
Ibaraki, JP
Employees
Employees
1162% increase
Employees
11033% increase
Employees
795% increase
Employees
1441% decrease
Employees
4
Employees
576500% increase
Valuation ($)
Valuation ($)
280.8 m
Valuation ($)
497.6 m
Valuation ($)
1.1 b
Valuation ($)
N/A
Valuation ($)
N/A
Valuation ($)
N/A
Twitter followers
Twitter followers
N/A
Twitter followers
1.2 k
Twitter followers
1.1 k
Twitter followers
578
Twitter followers
N/A
Twitter followers
204
Number of tweets (last 30 days)
Number of tweets (last 30 days)
N/A
Number of tweets (last 30 days)
9
Number of tweets (last 30 days)
4
Number of tweets (last 30 days)
N/A
Number of tweets (last 30 days)
N/A
Number of tweets (last 30 days)
8
Average likes per tweet (last 30 days)
Average likes per tweet (last 30 days)
N/A
Average likes per tweet (last 30 days)
3.2
Average likes per tweet (last 30 days)
5.3
Average likes per tweet (last 30 days)
N/A
Average likes per tweet (last 30 days)
N/A
Average likes per tweet (last 30 days)
N/A
Percentage of tweets with engagement (last 30 days)
Percentage of tweets with engagement (last 30 days)
N/A
Percentage of tweets with engagement (last 30 days)
77.78%
Percentage of tweets with engagement (last 30 days)
100%
Percentage of tweets with engagement (last 30 days)
N/A
Percentage of tweets with engagement (last 30 days)
N/A
Percentage of tweets with engagement (last 30 days)
N/A
Alexa Website Rank
Alexa Website Rank
N/A
Alexa Website Rank
271670
Alexa Website Rank
506467
Alexa Website Rank
N/A
Alexa Website Rank
727606
Alexa Website Rank
516238
Employee Rating
Employee Rating
4.3
Employee Rating
4
Employee Rating
3.2
Employee Rating
2.9
Employee Rating
N/A
Employee Rating
3.5

Financial

Revenue (est.)
Revenue (est.)
$33.9m (FY, 2021)
Revenue (est.)
$25.2m (FY, 2016)
Revenue (est.)
$69.9m (FY, 2021)
Revenue (est.)
$295k (FY, 2019)
Revenue (est.)
N/A
Revenue (est.)
N/A
Cost of goods
Cost of goods
$1.3m (FY, 2021)
Cost of goods
N/A
Cost of goods
N/A
Cost of goods
N/A
Cost of goods
N/A
Cost of goods
N/A
Gross profit
Gross profit
$32.6m (FY, 2021)
Gross profit
N/A
Gross profit
N/A
Gross profit
$295k (FY, 2019)
Gross profit
N/A
Gross profit
N/A
Net income
Net income
($230m) (FY, 2021)
Net income
($13.7m) (FY, 2016)
Net income
($139.3m) (FY, 2021)
Net income
($357.3m) (FY, 2019)
Net income
N/A
Net income
N/A

Operating

Patents (US)
Patents (US)
N/A
Patents (US)
7 (Apr, 2017)
Patents (US)
N/A
Patents (US)
405 (Sep, 2022)
Patents (US)
N/A
Patents (US)
N/A

Funding

Total funding raised
Total funding raised
$ 526m
Total funding raised
$ 219.5m
Total funding raised
$ 56m
Total funding raised
$ 30m
Total funding raised
$ 43.4m
Total funding raised
$ 3.5m
For sources of this data, please see the company profile

View company profiles

Mersana Therapeutics
HQ
Cambridge, US
Employees
110↑ 33% increase

Mersana Therapeutics is a clinical-stage biotechnology company developing antibody-drug conjugate (ADC) platforms.

View company
ImmunoGen
HQ
Waltham, US
Employees
79↑ 5% increase

ImmunoGen is a biotechnology company focused on the development of antibody-drug conjugates (ADCs) to improve outcomes for cancer patients.

View company
Immunomedics
HQ
Morris Plains, US

Immunomedics is a developer of monoclonal antibody-based products for the targeted treatment of cancer.

View company
Araris Biotech
HQ
Zürich, CH
Employees
4

Araris Biotech is a biotechnology company with a new antibody-drug conjugate (ADC)-linker technology.

View company